EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 126.74

Change

+0.94 (+0.75)%

Market Cap

USD 0.70B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.08 (+0.17%)

USD 502.95B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.02 (+0.14%)

USD 191.96B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.05 (+0.18%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.06 (+0.21%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.07 (+0.27%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

-1.24 (-0.89%)

USD 102.11B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.05%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.08 (+0.16%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+4.10 (+0.77%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.04 (+0.15%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.04% 94% A 91% A-
Dividend Return 1.17% 42% F 28% F
Total Return 21.21% 95% A 92% A
Trailing 12 Months  
Capital Gain 17.11% 71% C- 71% C-
Dividend Return 1.37% 40% F 26% F
Total Return 18.49% 74% C 73% C
Trailing 5 Years  
Capital Gain 51.68% 68% D+ 69% C-
Dividend Return 5.57% 60% D- 33% F
Total Return 57.25% 72% C 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.24% 57% F 56% F
Dividend Return 7.14% 60% D- 57% F
Total Return 0.91% 74% C 47% F
Risk Return Profile  
Volatility (Standard Deviation) 8.31% 65% D 72% C
Risk Adjusted Return 86.00% 91% A- 91% A-
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike